Aclaris Therapeutics
Logotype for Aclaris Therapeutics Inc

Aclaris Therapeutics (ACRS) investor relations material

Aclaris Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Aclaris Therapeutics Inc
Jefferies Global Healthcare Conference summary16 Nov, 2026

Pipeline updates and priorities

  • Bosakitug, a TSLP monoclonal antibody, missed the atopic dermatitis endpoint; the small study showed robust Th1, Th17 and Th2 pharmacodynamic responses, while single-agent TSLP was not part of the base plan.

  • Modzatinib 2138’s oral lichen planus study started last week and will cover mucosal, cutaneous and scalp phenotypes.

  • The 9494 next-generation ITK program completed required toxicology; filing is planned in the coming weeks, followed by SAD/MAD studies and proof of concept in 2027.

  • 9494 is being developed for TH2-based oral indications, potentially atopic disease or asthma; disease-related measures such as elevated FeNO may be included in MAD work.

  • A second indication for the 052 bispecific, either asthma or atopic dermatitis, is expected to be selected before year-end; designs may include a positive control or Dupixent failures.

052 bispecific and EoE strategy

  • EoE is now the lead indication for 052; tezepelumab’s positive data increased the rationale for a larger study focused initially on EoE.

  • KOLs cited rising EoE prevalence, potentially exceeding 1 million patients, and TSLP’s potential to address broader inflammatory pathways beyond eosinophils.

  • The EoE study is expected in 2027, with histologic, symptom and endoscopic outcomes; the aim is an efficient design that moves rapidly from phase 2 toward registration.

  • Target profile includes faster onset and greater depth or breadth of response; management also anticipates evaluating induction and maintenance approaches and longer dosing intervals.

Oral lichen planus study

  • The 2138 basket study starts with oral disease, then plans cutaneous and scalp cohorts; target enrollment is 35–40 patients, with interim analysis after ~60% reach week 16.

  • ODSS is the primary endpoint; IGA and patient-reported outcomes are also included. ODSS is a continuous 0–106 measure and was used to power the initial cohort.

  • After interim results, the plan is to consult the FDA on the registrational program; Fast Track designation enables further agency interaction.

  • Management cited ITK’s upstream mechanistic fit with T-cell receptor-driven disease and viewed an ODSS response near 50% as compelling.

  • A recent topical corticosteroid study in milder oral disease showed a 20% response rate; management noted the different disease severity and lower baseline ODSS scores.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Aclaris Therapeutics earnings date

Logotype for Aclaris Therapeutics Inc
Q4 202626 Feb, 2027
Aclaris Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Aclaris Therapeutics earnings date

Logotype for Aclaris Therapeutics Inc
Q4 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily engaged in the development of novel drug candidates for immuno-inflammatory diseases. Leveraging its core expertise in drug discovery, development, and kinase inhibition, Aclaris focuses on creating small molecule therapies for people affected by underserved immuno-inflammatory conditions. Its proprietary KINect® technology platform enables the development of clinical candidates targeting challenging kinases with novel approaches. Additionally, Aclaris operates Confluence Discovery Technologies, Inc., a full-service drug discovery and early development contract research organization. This subsidiary offers research partnership services across therapeutic areas and gene families, with expertise in a range of scientific disciplines including cell and molecular biology, biochemistry, enzymology, and immunology. he company is headquartered in Wayne, Pennsylvania, and its shares are listed on the Nasdaq.